Aducanumab: Biogen to seek US FDA approval

Written by Kimberley Ndungu, Future Science Group

Biogen (MA, USA) and Eisai Co. (Tokyo, Japan) have announced plans to pursue regulatory approval for aducanumab as a treatment for early Alzheimer’s disease (AD) after consultation with the US FDA. If approved, aducanumab would be the first line of therapy to reduce the clinical decline of AD and the first therapy to demonstrate the clinical benefit of removing amyloid beta. “With such a devastating disease that affects tens of millions worldwide, today’s announcement is truly heartening in the fight against Alzheimer’s. This is the result of ground-breaking research and is a testament to Biogen’s steadfast determination to follow the...

To view this content, please register now for access

It's completely free